FEM1B — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL25171623	0.68	3/20
SCHEMBL23804993	0.67	3/20
SCHEMBL23817980	0.62	3/20
SCHEMBL30132888	0.62	3/20
SCHEMBL23804989	0.61	3/20
SCHEMBL30132890	0.61	3/20
SCHEMBL23818422	0.60	3/20
SCHEMBL25455734	0.60	3/20
SCHEMBL23804984	0.59	3/20
SCHEMBL23817965	0.59	3/20
SCHEMBL23818590	0.59	3/20
SCHEMBL30132893	0.59	3/20
SCHEMBL23818425	0.57	3/20
SCHEMBL23818554	0.55	3/20
SCHEMBL23817939	0.52	3/20
SCHEMBL23818387	1.00	2/20
SCHEMBL30132892	1.00	2/20
SCHEMBL25455185	0.93	2/20
SCHEMBL25455775	0.90	2/20
SCHEMBL23818550	0.86	2/20

Clinical trials — most relevant to FEM1B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Treatment of Ectopic Calcification in Fahr's Disease or Syndrome	PHASE2	RECRUITING
Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100	PHASE1/PHASE2	COMPLETED
Human MATER and Idiopathic Infertility	nan	COMPLETED
Epidemiology of Pituitary Tumours: Prevalence of Associated Neoplasia	nan	UNKNOWN
Institution of an Italian Multicenter Database of Patients With Multiple Endocrine Neoplasia Type 1 (MENNET1 Database)	nan	NOT_YET_RECRUITING
Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer	nan	COMPLETED
Study of the Genetic and Epigenetic Causes of Recurrent Hydatidiform Moles	nan	ACTIVE_NOT_RECRUITING
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic	nan	COMPLETED
The Genetics of Chiari Type I Malformation	nan	COMPLETED
Genetic Analysis of Fraser Syndrome and Fryns Syndrome	nan	COMPLETED
Diaphragmatic Hernia Research & Exploration, Advancing Molecular Science	nan	RECRUITING
Study of Skeletal Disorders and Short Stature	nan	COMPLETED
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders	nan	COMPLETED
Microcephaly Genetic Deficiency in Neural Progenitors	nan	COMPLETED
Genes Modulating the Severity of Aortic Aneurysms (MSF1-TGFBR2)	nan	UNKNOWN
Genetic Mechanisms and Additional Risk Factors Underlying Hip Dysplasia	nan	COMPLETED
Familial Intracranial Aneurysm Study II	nan	COMPLETED
Longitudinal Studies of Patient With FPDMM	nan	RECRUITING
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders	nan	RECRUITING
Stone Centre Urine and Serum Bank	nan	UNKNOWN
Natural History Study of FDXR Mutation-related Mitochondriopathy	nan	COMPLETED
MEHMO Natural History and Biomarkers	nan	RECRUITING
Biomarkers in SCOTland CardiomyopatHy Registry (Bio-SCOTCH)	nan	RECRUITING
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Maternal Genes and Epimutations: Beckwith-Wiedemann Syndrome & Reproductive Risks	nan	RECRUITING
Genetic Evaluation of Families With Endocrine Cancers	nan	COMPLETED
A Study of Multilocus Methylation Abnormalities in Subjects With Imprinting Disorders	nan	NOT_YET_RECRUITING
Investigation of Copy Number Variations and Genetic Variants in POI	nan	RECRUITING
Genetic Analysis of Inherited Urologic Malignant Disorders: Collection of Samples	nan	COMPLETED
Stone Disease in Children and Their Families	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a FEM1B binder may also engage these)

Protein	Name	Similarity
Q9Z2G0	—	1.000	Q9Z2G0 →
P0C6P7	—	1.000	P0C6P7 →
Q6GPE5	—	1.000	Q6GPE5 →
Q5ZM55	—	1.000	Q5ZM55 →
Q8CEF1	—	0.990	Q8CEF1 →
Q7T3P8	—	0.986	Q7T3P8 →
A7MB89	—	0.985	A7MB89 →
Q29RM5	—	0.983	Q29RM5 →
Q9Z2G1	—	0.982	Q9Z2G1 →
Q9BSK4	—	0.981	Q9BSK4 →
Q4V890	—	0.981	Q4V890 →
Q8C0T1	—	0.981	Q8C0T1 →
Q2T9K6	—	0.979	Q2T9K6 →
Q96JP0	—	0.979	Q96JP0 →
Q6P9Z4	—	0.979	Q6P9Z4 →
Q9Y574	—	0.975	Q9Y574 →
Q9WV71	—	0.974	Q9WV71 →
Q9VFD5	—	0.973	Q9VFD5 →
Q8VHS6	—	0.973	Q8VHS6 →
Q96Q27	—	0.973	Q96Q27 →
Q9H0C1	—	0.972	Q9H0C1 →
Q810B6	—	0.971	Q810B6 →
Q6P3X3	—	0.971	Q6P3X3 →
Q9Y575	—	0.971	Q9Y575 →
Q5R981	—	0.970	Q5R981 →
P0C927	—	0.970	P0C927 →
Q9P2R3	—	0.970	Q9P2R3 →
Q8HXA6	—	0.970	Q8HXA6 →
ATP6V1H	V-type proton ATPase subunit H	0.970	landscape →
Q0IIZ5	—	0.970	Q0IIZ5 →